Seattle Genetics Inc (SGEN)

Add to Watchlists
Create an Alert
69.16 +1.13  +1.66% NASDAQ May 24, 16:59 Delayed 2m USD
View Full Chart
SGEN Price Chart
View All Key Stats

SGEN Key Stats

View All SGEN News

SGEN News

View All Events

SGEN Events

Date Type Description
07/26/2019 16:30 EDT Misc Seattle Genetics Inc Second Quarter Earnings Conference Call in 2019
07/26/2019 Earnings Seattle Genetics Inc Second Quarter Earnings in 2019 Release
05/20/2019 Misc Seattle Genetics Inc Annual General Meeting in 2018
04/25/2019 16:30 EDT Misc Seattle Genetics Inc First Quarter Earnings Conference Call in 2019
04/25/2019 Earnings Seattle Genetics Inc First Quarter Earnings in 2019 Release
02/07/2019 16:30 EST Misc Seattle Genetics Inc Fourth Quarter Earnings Conference Call in 2018
02/07/2019 Earnings Seattle Genetics Inc Fourth Quarter Earnings in 2018 Release
02/07/2019 Misc Seattle Genetics Inc Annual Report in 2018
10/25/2018 16:30 EDT Misc Seattle Genetics Inc Third Quarter Earnings Conference Call in 2018
10/25/2018 Earnings Seattle Genetics Inc Third Quarter Earnings Results in 2018
View All Performance Charts

SGEN Total Returns Comparison

SGEN Fundamentals

Income Statement View Statement

Revenue (TTM) 709.31M
Total Expenses (TTM) 929.12M
Net Income (TTM) -124.31M

Balance Sheet View Statement

Total Assets (Quarterly) 1.593B
Total Liabilities (Quarterly) 279.19M
Shareholders Equity (Quarterly) 1.313B

Cash Flow Statement View Statement

Cash from Operations (TTM) -113.60M
Cash from Investing (TTM) -59.18M
Cash from Financing (TTM) 70.16M

SGEN Ratings

Advertisement

SGEN One Page Reports

Edit

Profile

  • URL: http://www.seattlegenetics.com
  • Investor Relations URL: http://investor.seattlegenetics.com/phoenix.zhtml?c=124860&p=irol-IRHome
  • HQ State/Province: Washington
  • Sector: Healthcare
  • Industry: Biotechnology
  • Equity Style: Mid Cap/Growth
  • Next Earnings Release: Jul. 26, 2019
  • Last Earnings Release: Apr. 25, 2019
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A
  • Description: Seattle Genetics is a biotech firm focused on the development of monoclonal antibody-based therapies. The company's lead product, Adcetris, has received approval for advanced frontline, relapsed/refractory and post-consolidation Hodgkin lymphoma, anaplastic large-cell lymphoma, and two other subtypes of cutaneous T-cell lymphoma. The company has several other early-stage programs in trials. Seattle Genetics also licenses its antibody-drug conjugate technology to a number of leading biotechnology and pharmaceutical companies.

SGEN Analyst Coverage

Consensus Recommendations
Buy Recommendations Upgrade
Outperform Recommendations Upgrade
Hold Recommendations Upgrade
Underperform Recommendations Upgrade
Sell Recommendations Upgrade
Consensus Recommendation Upgrade
Consensus Rating Upgrade
Target Price
Price 69.16
Price Target Upgrade
Price Target Upside (Daily) Upgrade

SGEN Comparables

Edit
RGEN Repligen Corp
INNT Innovate Biopharmaceuticals Inc
CELG Celgene Corp
MRK Merck & Co Inc
BMY Bristol-Myers Squibb Co

Excel Add-In Codes

  • Name: =YCI("SGEN","name")
  • Description: =YCI("SGEN","description")
  • Sector: =YCI("SGEN","sector")
  • Industry: =YCI("SGEN","industry")
  • Est. Current Fiscal Year End: =YCI("SGEN","fye")

To find the codes for any of our financial metrics, see our Complete Reference of Metric Codes.

Access our powerful Excel Add-in with a YCharts Professional Membership. Learn More.

Other SGEN Resources

Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.

Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.